Call: 0123456789 | Email: info@example.com

Prices of Golds in market

Prices of Golds in market


Prices of Golds in market

As the price of gold bullion corrected in March, central banks around the world seized the opportunity to buy. The International Monetary Fund released a report that revealed that, in March of 2012, central banks not only took advantage of the lower prices in gold bullion to buy, but they were also buying in large quantities.

Mexico bought 16.8 tons in March, while Turkey added 11.5 tons and Kazakhstan picked up 4.3 tons. Russia has been fairly vocal about its gold bullion buying and remained true to form by purchasing 15.6 tons of the shiny metal last month. click here for related details.

In total, 57.9 tons of gold bullion was purchased by central banks around the world in March. To put some perspective on this number, in 2011, central banks bought just under 440 tons of gold bullion, as reported by the World Gold Council. This was close to a 50-year high in gold bullion purchases.

It is, of course, difficult to extrapolate from March’s numbers, but taking into account the first three months of the year, it is possible that, should this pace of gold bullion buying by the central banks around the world in 2012 continue, the total will reach 700 tons of gold bullion purchased, which would make 2012 a record year.

Of course, many of the G7 nations—U.S., U.K., Canada, France, Germany, Italy and Japan—are confused by these purchases. Their contention is that gold bullion is a commodity that actually does not have many uses outside of jewelry.

The nations outside the G7 have long histories and have lived through the financial crisis and/or have been passed down stories of the financial crisis from their ancestors. They understand that gold bullion has been used as money for 5,000 years. They believe that gold bullion is not a commodity, but a monetary unit. In times of crisis, money is debased by money printing, which results in citizens losing their purchasing power and eventually everything that they worked for. Gold bullion preserves purchasing power because it cannot be printed or manipulated.

Prices of Golds in market

They understand from the past that the money printing that is currently taking place is on a scale never witnessed before in history. Trillions upon trillions are being created by the U.S., Japan, the U.K., and the European Union. The contention is that there are no consequences to this money printing, but these central banks who reside in countries that have a long history beg to differ. They are speaking with their actions, not words.

The other peculiar thing to note is that, while the G7 central banks claim that gold bullion is not money—and Federal Reserve Chairman Ben Bernanke went further to deny that gold bullion was money when asked directly by Congressman Ron Paul—the G7 countries have not sold one ounce of gold bullion in the last five years.

The 17 nations of the European Union hold the largest amount of gold bullion in the world at just over 10,400 tons, while the central bank of the U.S. holds the second largest amount of gold bullion in the world at 8,133 tons.

If gold bullion is just a commodity, then why not sell it? I think investors, as the saying goes, should do as central banks do, not as they say.

The bull market in gold bullion, in my opinion, is alive and well and has a lot more to go on the upside, because of money printing, which has and will continue to destroy purchasing power, as it has done in the past.

I’m following what central banks are doing.

RSS Stock Market

  • Verastem Inc. (VSTM:NASDAQ) September 29, 2020
    Verastem Inc. (VSTM:NASDAQ) Verastem Inc. (VSTM:NASDAQ) has a market cap of $80M. A Biotech Watchlist veteran, Verastem is attempting to lift itself up in the wake of the significant Phase 2 COMMAND trial disappointment. New preclinical information has risen with respect to the utilization of central bond kinase (FAK) and protein tyrosine kinase-2 (PYK2) inhibitors […]
  • Tokai Pharmaceuticals’ (NASDAQ:TKAI) September 29, 2020
    Tokai Pharmaceuticals’ (NASDAQ:TKAI) The business case for Tokai Pharmaceuticals’ (NASDAQ:TKAI) lead prostate malignancy venture, galeterone, was flawed well before late 70% breakdown in the gathering’s share price. Also, the issues were more basic even than the way that the maim safe prostate growth field has been shaken up to the point of being unrecognizable by […]
  • Tonix Pharmaceuticals Holding Corp. (TNXP) September 29, 2020
    Tonix Pharmaceuticals Holding Corp. (TNXP) As of late, Tonix Pharmaceuticals Holding Corp. (TNXP) reported that it had fizzled its stage 3 trial in patients with Fibromyalgia. The stage 3 trial, known as the “Certify” trial, neglected to meet on the essential endpoint of the study. The trial was outlined in such an approach to test […]
  • Threshold Pharmaceuticals (THLD) September 29, 2020
    Threshold Pharmaceuticals (THLD) Shares of Threshold Pharmaceuticals (THLD) were spiking on substantial exchanging volume as kindred medication producer Medivation (MDVN) consented to be purchased by Pfizer (PFE) for $14 billion. A South San Francisco-based clinical stage biopharmaceutical organization concentrated on the disclosure and improvement of disease therapeutics. Around 14.41 million of the organization’s shares changed […]
  • Theravance Biopharma (NASDAQ:TBPH) September 29, 2020
    Theravance Biopharma (NASDAQ:TBPH) With no uncertainty, Theravance Biopharma (NASDAQ:TBPH) is one of the best outperformers of the previous 12 months. It has outflanked IBB by 140% and the NASDAQ by 116%. This may have driven a few financial specialists to trust the gathering won’t keep going long any longer. Before that, the stock had really […]
  • StemCells (NASDAQ:STEM) September 29, 2020
    StemCells (NASDAQ:STEM) StemCells (NASDAQ:STEM) went up 598.55% in a solitary day. StemCells surged altogether taking after its declaration of going to enter an opposite merger with an Israeli organization named Microbot Medical. Microbot Medical is a privately owned business, by converging with StemCells, it will end up being an open organization under StemCells’ available posting. […]
  • Synthetic Biologics Inc. (SYN) September 29, 2020
    Synthetic Biologics Inc. (SYN) Numerous financial specialists like to search for momentum stocks, yet this can be extremely difficult to characterize. There is incredible level headed discussion with respect to which measurements are the best to concentrate on in such manner, and which are not by any means quality pointers of future execution. Luckily, with […]
  • Synergy Pharmaceuticals (NASDAQ:SGYP) September 29, 2020
    Synergy Pharmaceuticals (NASDAQ:SGYP) Synergy Pharmaceuticals (NASDAQ:SGYP) is a little top exploration stage biotech organization recorded on the Nasdaq. With a share price around $3 and a business sector top around $600 million, SGYP will have a noteworthy impetus in IBS-Constipation in Q3 2016. In the event that this Phase 3 trial is effective, the stock […]
  • Immune Pharmaceuticals (NASDAQ:IMNP) September 29, 2020
    Immune Pharmaceuticals (NASDAQ:IMNP) Immune Pharmaceuticals (NASDAQ:IMNP) is pushing forward with a multi-pronged way to deal with battling malignancy. Over the previous year, it has essentially extended its immuno-oncology (I/O) senior initiative to drive this exertion forward. Their endeavors in I/O are going up by Miri Ben-Ami, MD, a previous senior official at Teva, Monica Luchi, […]
  • Ignyta Inc. (RXDX:NASDAQ) September 29, 2020
    Ignyta Inc. (RXDX:NASDAQ) Ignyta Inc. (RXDX:NASDAQ) has a $420M market cap. Ignyta takes a targeted approach to oncology, focusing on integrated therapies and diagnostics. This methodology derisks its clinical trials. The company has an efficient “basket design” that allows for multiple data points, a big pipeline and an aggressive business development strategy. The company is […]